Analyze What Papers Actually Reported

Visualize: method-feature landscape (reported metrics)

Interpretation (visual first)

The bar chart displays one representative published performance number per method to orient expectations: SITAR's AUC/AUPR for drug-target prediction (high discriminative performance), PathDSP's low MAE for drug sensitivity prediction when integrating pathway features, Pharmacogx's PGx classifier AUROC ~0.8 for pharmacogene prioritization, and ProtSEC's reported lightweight memory (~0.4 GB) as an indicator of computational footprint for embedding methods. See citations below for full experimental context and limitations.

Plan: reproducible method-comparison pipeline (visualize → evaluate → explain)

1. Define scope & tasks: two tasks — (A) drug-target interaction (DTI) prediction (binary) and (B) drug-response regression (continuous IC50/MAE). Use public benchmarks that map to the methods' original domains (DrugBank/Matador-derived DTI set for SITAR-like; GDSC/CCLE for PathDSP-style drug sensitivity) to preserve comparability.
   Rationale: methods emphasize different downstream tasks; compare within task-appropriate baselines.
2. Assemble datasets & canonical splits:
   • DTI: curated positive pairs from DrugBank/Matador; construct realistic negatives via decoy strategies (block‑aware sampling) to avoid inflated performance from naive negatives.
   • Drug-response: GDSC (drug–cell-line IC50) as training benchmark, CCLE as external test for transferability following PathDSP protocols.
   • Auxiliary data: drug SMILES (PubChem/DrugBank), target sequences (UniProt), side-effect profiles (SIDER), ATC codes, PPI (STRING), pathway annotations (KEGG/Reactome), PharmGKB PGx pairs for pharmacogene comparisons.
3. Implementable methods (reproducible minimal implementations) — implement or re-run canonical variants with standardized inputs:
   • SITAR-style similarity-fusion: compute multiple drug-drug similarities (Morgan fingerprints/Tanimoto, SEA/ligand overlap if available, side-effect Jaccard, ATC semantic), gene-gene similarities (sequence similarity, GO semantic, PPI distance), combine feature pairs and train a logistic/regression classifier (regularized logistic or CatBoost as robust alternative). Use SITAR's wrapper feature-selection and 10-fold CV for parity SITAR multi-similarity framework.
   • Graph/random-walk embeddings (Juxtapose-style) applied to drug-gene or gene co-expression / drug–target bipartite graphs: generate node embeddings using random-walk + word2vec skip-gram, then use cosine similarity or train downstream classifier/regressor. Juxtapose shows topology-preserving embeddings useful for alignment and module detection — adapt for DTI by building a drug–gene bipartite graph and learning embeddings for both node types Juxtapose random-walk embeddings.
   • Pathway-aware chemogenomic model (PathDSP): compute drug chemical fingerprints + drug-gene network features + cell-line pathway enrichment (ssGSEA or NetPEA) and fit a neural network (FNN) or gradient-boosted trees; use SHAP for explanations and LODO/LOCO CVs and CCLE external test as in PathDSP PathDSP pathway+chem model.
   • Knowledge-graph / biomedical embeddings + ML (Pharmacogx-inspired): use Bioteque/knowledge-graph embeddings to represent genes and drugs, combine with gene descriptors (ProtT5 / ESM) and drug descriptors and train LightGBM ensembles; expect AUROC ≈0.8 for PGx prioritization per pharmacogx report — adapt for DTI/PGx ranking tasks Pharmacogx KG+ML pipeline.
   • Transformer / attention cross‑modal (MIDI-like): design a cross-attention model that attends from drug atom/substructure tokens to gene-expression/feature tokens for explainable attention maps; use as an upper-bound experimental method for explainability benchmarking — note MIDI used small drug set (24 drugs) and reported gains but generalizability needs validation MIDI attention cross-modal model.
4. Standardized evaluation metrics:
   • DTI (classification): ROC AUC, PR AUPR, precision@k (top-10), calibration (Brier), and robustness to negative-sampling schemes.
   • Drug-response (regression): MAE/RMSE, R2, Spearman rank, and external transfer (GDSC→CCLE) performance delta as measure of generalizability (PathDSP used MAE ≈0.24 baseline) PathDSP performance.
   • Compute & scalability: embedding time, peak RAM, index size (ProtSEC reported ~0.4 GB peak RAM for 5K seqs), and throughput (queries/sec). Use ProtSEC's compute metrics to set expectations for light-weight embeddings when relevant ProtSEC compute metrics.
5. Explainability & biological validation:
   • Apply SHAP/Integrated Gradients for feature attribution on PathDSP and SITAR feature pairs; for graph/attention methods inspect attention maps and neighborhood subgraphs to produce drug→gene reasoning chains.
   • Cross-check top predicted drug–gene links against DGIdb, Drug Repurposing Hub, OnSIDES wADEs, and literature; measure overlap enrichment (Fisher’s exact) as partial external validation (Pharmacogx and AdiposityGSEM used DGIdb/DRH approaches) Adiposity study drug-gene network.
6. Robustness & fairness checks:
   • Negative sampling sensitivity (for DTI), AUROC vs AUPR tradeoffs, evaluation on held-out drug scaffolds and held-out genes (to test real generalization), and performance stratified by drug class (e.g., small molecules vs biologics) and target class (GPCRs, kinases).
   • Assess ancestry/population biases when using PGx datasets (Pharmacogx flagged AFR-specific variant context and generalizability limits) Pharmacogx generalizability note.
7. Implementation & reproducibility:
   • Repository template: data/ splits/ preproc scripts, method folders with Docker/Singularity containers, unit tests for feature pipelines, and continuous evaluation notebooks. Use snakemake/nf-core for pipeline orchestration and provide prebuilt datasets for quick repro runs.
   • Baseline hardware targets: small workstation (32GB RAM, 8 CPU + 1 GPU) and cluster config; include lightweight and heavy variants (ProtSEC-like low-memory vs PLM-based high-memory) for compute cost comparisons.
8. Deliverables:
   • Ranked method matrix (performance, compute, interpretability, transferability), calibration plots, PR/ROC curves, precision@k tables, SHAP heatmaps and attention-graph visualizations, and a final README with recommended methods per use-case (fast screening vs interpretable target discovery vs accurate sensitivity prediction).
   • Interactive dashboard (Streamlit/Voila) to explore predictions and inspect top drug-gene rationales; include exportable DGIdb/DRH overlap lists for experimental follow-up.

Concrete first-week milestones (iterative, testable)

1. Day 1–2: dataset assembly & canonical splits; implement negative-sampling strategies and baseline metrics. (Deliver: canonical split files + README)
2. Day 3–5: implement SITAR-style similarity pipeline and PathDSP pipeline with minimal features; run cross-validated baselines. (Deliver: baseline AUC/AUPR, MAE results + reproducible notebook)
3. Day 6–7: implement Juxtapose/graph-embedding pipeline and a KG-embedding + LightGBM baseline (pharmacogx-style); run head-to-head on DTI task. (Deliver: ranking matrix & initial explainability outputs)

Caveats, biases & blindspots

• Heterogeneous labels and negative‑set construction can heavily bias classifier metrics; prefer precision@k and external validations (DGIdb overlap) over single-number AUC claims (SITAR noted sensitivity to dataset curation) SITAR limitations.
• Transformer/attention methods (MIDI) may show strong within-sample interpretability but suffer generalization on small drug sets; attention ≠ causation; claims require biological follow-up MIDI caution.
• KG and PBPK integrations (pharmacogx) are powerful for translational PGx prioritization but require domain-specific validation (PBPK/NLME) and can be confounded by missing variant functional data and intronic-dominant variant sets (Pharmacogx notes >80% intronic variants) Pharmacogx limitations.

Next step (one-click)

If you want an automated run that assembles the exact datasets, executes these pipelines on your infrastructure or our cloud container, and returns full evaluation figures and interpretable drug→gene lists, click the Run AI Scientist Analysis button below.

Key citations used in this plan

• SITAR multi-similarity framework
• Juxtapose random-walk embeddings
• PathDSP pathway+chem model
• Pharmacogx KG+ML pipeline
• MIDI attention cross-modal model
• ProtSEC compute baseline

Confidence & limitations: the pipeline above is evidence-grounded using the cited primary methods and their reported metrics; expected outcomes depend strongly on dataset curation choices, negative sampling, and task alignment—we recommend the iterative automated run to quantify these sensitivities on your exact data.